Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 62Glioblastoma 52Lung Neoplasms 49Breast Neoplasms 46Prostatic Neoplasms 39Head and Neck Neoplasms 38Squamous Cell Carcinoma of Head and Neck 33Esophageal Neoplasms 30Brain Neoplasms 28Lymphoma 27Gliosarcoma 27Rectal Neoplasms 24Hodgkin Disease 24Pancreatic Neoplasms 22Adenocarcinoma Of Esophagus 22Central Nervous System Neoplasms 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 20Neoplasms 20Lymphoma, Non-Hodgkin 17Leukemia 17Glioma 17Burkitt Lymphoma 16Sarcoma 15Lymphoma, Large B-Cell, Diffuse 15Lymphoma, Follicular 14Carcinoma, Squamous Cell 14Colorectal Neoplasms 13Astrocytoma 13Neoplasm Metastasis 12Melanoma 12

Interventions

trastuzumab biosimilar HLX02 1Trastuzumab 1Taxes 1Radiotherapy 1Radiation 1Paclitaxel 1PF-05280014 1Ontruzant 1Ogivri 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Bladder Urothelial Carcinoma × Radiotherapy × Clear all
NCT00238420 2022-07-19

Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
70 enrolled 10 charts
Genitourinary

Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡